Dupilumab De-escalation in Pediatric Atopic Dermatitis
Phase 4
30
about 3.1 years
1–17
1 site in MD
About this study
Researchers are testing whether children with atopic dermatitis can stop or reduce their dupilumab treatment if they have achieved good control of their skin condition. The trial will last for 1124 days and involve approximately 30 children aged 1 to 17 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dupilumab - Discontinuation
- 2.Take Dupilumab - Dose Reduction
- 3.Take Dupilumab - Standard Dose
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Adverse Events After Dupilumab Dose-reduction or Discontinuation, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Depressive Symptoms questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Itch questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Problem questionnaire score
Dermatology